| 2.46 0.16 (6.96%) | 10-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.1 |
1-year : | 3.62 |
| Resists | First : | 2.66 |
Second : | 3.1 |
| Pivot price | 2.41  |
|||
| Supports | First : | 2.35 |
Second : | 2.16 |
| MAs | MA(5) : | 2.3 |
MA(20) : | 2.44 |
| MA(100) : | 2.57 |
MA(250) : | 3.44 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 38.5 |
D(3) : | 26.9 |
| RSI | RSI(14): 50.7 |
|||
| 52-week | High : | 7.19 | Low : | 1.79 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ HURA ] has closed below upper band by 39.9%. Bollinger Bands are 28.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.5 - 2.51 | 2.51 - 2.52 |
| Low: | 2.23 - 2.24 | 2.24 - 2.25 |
| Close: | 2.44 - 2.46 | 2.46 - 2.48 |
TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.
Mon, 27 Oct 2025
Tuhura Biosciences Advances in Merkel Cell Carcinoma Treatment Study - TipRanks
Mon, 27 Oct 2025
Tuhura Biosciences’ Promising Phase 1 Trial: A Potential Game-Changer in Merkel Cell Carcinoma Treatment - TipRanks
Thu, 23 Oct 2025
The recent pullback must have dismayed TuHURA Biosciences, Inc. (NASDAQ:HURA) insiders who own 43% of the company - Sahm
Thu, 16 Oct 2025
HURA Stock Price and Chart — NASDAQ:HURA - TradingView
Wed, 20 Aug 2025
TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference - Yahoo Finance
Thu, 14 Aug 2025
TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 51 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 35.7 (%) |
| Held by Institutions | 12.8 (%) |
| Shares Short | 2,300 (K) |
| Shares Short P.Month | 2,490 (K) |
| EPS | -0.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.37 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -3.33 |
| PEG Ratio | 0 |
| Price to Book value | 6.47 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.48 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|